Ionis Pharmaceuticals Announces $700 Million Convertible Senior Notes Offering
Reuters
Nov 18, 2025
Ionis Pharmaceuticals Announces $700 Million Convertible Senior Notes Offering
Ionis Pharmaceuticals Inc. has announced a proposed private offering of $700 million aggregate principal amount of Convertible Senior Notes due 2030. The company also plans to grant initial purchasers an option to buy up to an additional $70 million principal amount of notes within a 13-day period starting from the initial issuance date. The notes will be general unsecured obligations of Ionis and will accrue interest payable semiannually in arrears. Upon conversion, Ionis may settle the notes in cash, common stock, or a combination of both, at its discretion. The interest rate, initial conversion rate, and other terms will be determined at the time of pricing. Proceeds from the offering are expected to be used for repurchasing or repaying the company's 0% Convertible Senior Notes due 2026. No URL for the full prospectus is included in the document.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-284609), on November 17, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.